| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2112743 | Cancer Letters | 2014 | 9 Pages |
•We report a 1H NMR-based metabolic phenotyping study of breast cancer patients.•Serum NMR metabolic profiles discriminate metastatic breast cancer from the localized early disease.•Our model is validated with an independent cohort and provides high sensitivity and specificity.•Nine statistically significant metabolites involved in this discrimination are identified.
Breast cancer (BC) displays a high heterogeneity from histology to prognosis, metastatic evolution and treatment responses. We report here a 1H NMR-based metabolic phenotyping study aiming at identifying coordinated metabolic serum changes associated with advanced metastatic breast cancer (MBC) in comparison to the localized early disease (EBC). A model discriminating EBC and MBC patients is obtained (n = 85: 46 EBC and 39 MBC), and validated with an independent cohort (n = 112: 61 EBC and 51 MBC; 89.8% sensitivity, 79.3% specificity). We identify 9 statistically significant metabolites involved in this discrimination: histidine, acetoacetate, glycerol, pyruvate, glycoproteins (N-acetyl), mannose, glutamate and phenylalanine. This work illustrates the strong potential of NMR metabolic phenotyping for the diagnosis, prognosis, and management of cancer patients.
